CY1109734T1 - Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης - Google Patents
Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζηςInfo
- Publication number
- CY1109734T1 CY1109734T1 CY20101100028T CY101100028T CY1109734T1 CY 1109734 T1 CY1109734 T1 CY 1109734T1 CY 20101100028 T CY20101100028 T CY 20101100028T CY 101100028 T CY101100028 T CY 101100028T CY 1109734 T1 CY1109734 T1 CY 1109734T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- halogen
- hydrogen
- independently hydrogen
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει μεθόδους για τη θεραπευτική αντιμετώπιση της σχιζοφρένειας και/ή ανωμαλιών ρύθμισης της γλυκόζης σε έναν ασθενή χρήζοντα αυτής, και περιλαμβάνουν τη χορήγηση στον εν λόγω ασθενή μιας θεραπευτικά αποτελεσματικής ποσότητας μιας ένωσης του τύπου (I) όπου το m είναι 0, 1 ή 2, το n είναι 0, 1 ή 2, το p είναι 0 ή 1, έκαστο R είναι ανεξάρτητα υδρογόνο, αλογόνο, τριφθορομεθύλιο, C1-C6αλκύλιο, C1-C6αλκοξύ, βενζυλοξύ, υδροξύ, νιτρο- ή αμινο-ομάδα, έκαστο R1 είναι ανεξάρτητα υδρογόνο, C1-C6αλκύλιο, C1-C6αλκενύλιο, C1-C6αλκανοΰλιο, αλογόνο, κυανο-ομάδα, -C (O) C1-C6αλκύλιο, -C1-C6αλκυλένιoCN, -C1-C6αλκυλένιοNR'R" όπου τα R' και R" είναι έκαστο ανεξάρτητα υδρογόνο ή C1-C6αλκύλιο, -C1-C6αλκυλένιoOC(Ο)C1-C6αλκύλιο, ή -CH(OH)R4 όπου το R4 είναι υδρογόνο ή C1-C6αλκύλιο, το R2 είναι υδρογόνο, C1-C6αλκύλιο προαιρετικά υποκατεστημένο με αλογόνο, υδροξύ ή βενζυλοξύ, C1-C6αλκενύλιο, C1-C6αλκυνύλιο, -C02C1-C6αλκύλιο, ή -R5-NR' R" όπου το R5 είναι C1-C6αλκυλένιο, C1-C6αλκενυλένιο ή C1-C6αλκυνυλένιο και τα R' και R" είναι έκαστο ανεξάρτητα υδρογόνο, C1-C6αλκύλιο ή εναλλακτικά η ομάδα -NR'R" ως σύνολο είναι 1-πυρρολιδινύλιο, και το R3 είναι υδρογόνο, νιτρο-ομάδα, αμινο-ομάδα, αλογόνο, C1-C6αλκοξύ, υδροξύ ή C1-C6αλκύλιο, ή ένα φαρμακευτικά αποδεκτό άλας αυτής.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55845104P | 2004-04-01 | 2004-04-01 | |
EP05732721A EP1734959B1 (en) | 2004-04-01 | 2005-04-01 | Compounds for treating schizophrenia and/or glucoregulatory abnormalities |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109734T1 true CY1109734T1 (el) | 2014-09-10 |
Family
ID=34978926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100028T CY1109734T1 (el) | 2004-04-01 | 2010-01-11 | Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης |
Country Status (26)
Country | Link |
---|---|
US (1) | US20070129403A1 (el) |
EP (2) | EP2138176A1 (el) |
JP (1) | JP2007531730A (el) |
KR (1) | KR20070010161A (el) |
CN (1) | CN1946399A (el) |
AR (1) | AR048197A1 (el) |
AT (1) | ATE446754T1 (el) |
AU (1) | AU2005231446A1 (el) |
BR (1) | BRPI0509512A (el) |
CA (1) | CA2561162A1 (el) |
CL (1) | CL2009001605A1 (el) |
CY (1) | CY1109734T1 (el) |
DE (1) | DE602005017373D1 (el) |
DK (1) | DK1734959T3 (el) |
DO (1) | DOP2005000050A (el) |
ES (1) | ES2334241T3 (el) |
GT (1) | GT200500063A (el) |
IL (1) | IL178168A0 (el) |
MX (1) | MXPA06011222A (el) |
PA (1) | PA8628601A1 (el) |
PL (1) | PL1734959T3 (el) |
PT (1) | PT1734959E (el) |
SI (1) | SI1734959T1 (el) |
SV (1) | SV2006002069A (el) |
TW (1) | TW200602040A (el) |
WO (1) | WO2005097122A2 (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
CA2665698A1 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
AU2007307638A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
JP5714572B2 (ja) * | 2009-06-03 | 2015-05-07 | マーケット ユニバーシティー | 精神障害およびその症状の治療のためのkcnqカリウムチャネル活性の調節方法 |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
RU2544852C2 (ru) | 2009-10-14 | 2015-03-20 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
MY165117A (en) | 2010-02-26 | 2018-02-28 | Xenon Pharmaceuticals Inc | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
MX2019002265A (es) | 2016-08-24 | 2019-10-30 | Prilenia Therapeutics Dev Ltd | Uso de pridopidina para el tratamiento de la disminucion funcional. |
CN113840569A (zh) * | 2019-03-19 | 2021-12-24 | 剑桥认知有限公司 | 诊断精神病症和推荐用于精神病症的治疗的方法和用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
DE3852335T2 (de) * | 1987-04-24 | 1995-05-11 | Hoechst Roussel Pharma | N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel. |
US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
ES2174081T3 (es) * | 1995-07-27 | 2002-11-01 | Aventis Pharma Inc | Uso de n-(pirrol-1-il)piridinaminas sustituidas y no sustituidas como agentes anticonvulsivos. |
AU727775B2 (en) | 1996-01-17 | 2000-12-21 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
PT944648E (pt) | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
BR9810592A (pt) | 1997-07-16 | 2000-09-12 | Novo Nordisk As | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto |
GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de active Active
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
- 2005-04-01 EP EP09012248A patent/EP2138176A1/en not_active Withdrawn
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Application Discontinuation
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es active Active
- 2005-04-01 EP EP05732721A patent/EP1734959B1/en not_active Not-in-force
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en active Application Filing
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1734959T1 (sl) | 2010-02-26 |
EP1734959A2 (en) | 2006-12-27 |
DK1734959T3 (da) | 2010-03-08 |
GT200500063A (es) | 2005-10-14 |
KR20070010161A (ko) | 2007-01-22 |
PL1734959T3 (pl) | 2010-03-31 |
EP1734959B1 (en) | 2009-10-28 |
DOP2005000050A (es) | 2005-11-30 |
CN1946399A (zh) | 2007-04-11 |
CL2009001605A1 (es) | 2009-11-27 |
PA8628601A1 (es) | 2006-05-16 |
ATE446754T1 (de) | 2009-11-15 |
BRPI0509512A (pt) | 2007-09-11 |
JP2007531730A (ja) | 2007-11-08 |
AU2005231446A1 (en) | 2005-10-20 |
MXPA06011222A (es) | 2007-01-16 |
ES2334241T3 (es) | 2010-03-08 |
IL178168A0 (en) | 2006-12-31 |
US20070129403A1 (en) | 2007-06-07 |
PT1734959E (pt) | 2009-12-24 |
AR048197A1 (es) | 2006-04-05 |
SV2006002069A (es) | 2006-05-24 |
TW200602040A (en) | 2006-01-16 |
WO2005097122A2 (en) | 2005-10-20 |
DE602005017373D1 (de) | 2009-12-10 |
WO2005097122A3 (en) | 2006-02-02 |
EP2138176A1 (en) | 2009-12-30 |
CA2561162A1 (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109734T1 (el) | Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης | |
RU2324684C2 (ru) | Пиримидиновые производные | |
EA200700099A1 (ru) | Производные пиридина | |
EA200701808A1 (ru) | Производные тетрагидроиндолона и тетрагидроиндазолона | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
ATE517882T1 (de) | Chinolinderivate | |
EA200970913A1 (ru) | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов | |
EA200601747A1 (ru) | Три(цикло)замещённые амидные соединения | |
EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
EA200801041A1 (ru) | Ингибиторы мек и способы их применения | |
CY1108583T1 (el) | Μεθοδος για θεραπεια σοβαρης καρδιακης ανεπαρκειας και φαρμακο για αυτη | |
EA200501095A1 (ru) | Фенилацетамиды и их применение в качестве модуляторов глюкокиназы | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
NO20053748L (no) | Pyrrolopyridazinderivater. | |
RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
SE0401342D0 (sv) | Therapeutic compounds | |
EA200700642A1 (ru) | Способы лечения эпилептогенеза и эпилепсии | |
DK2040703T3 (da) | Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf | |
EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
EA200870577A1 (ru) | Конденсированные трициклические сульфонамидные ингибиторы гамма-секретазы |